Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL*) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial

Poster Presented at the International Society for Traumatic Stress Studies 32nd Annual Meeting in Dallas, TX, November 10, 2016

Gregory M. Sullivan, Judith F. Gendreau, R. Michael Gendreau, Amy Schaberg, Bruce L. Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Seth Lederman

The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD.

Poster Presented at the 2016 NEI Psychopharmacology Congress in Colorado Springs, CO, November 3-6, 2016

Gregory Sullivan, Judith Gendreau, R. Michael Gendreau, Amy Schaberg, Bruce Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Seth Lederman

A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD:
Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5

Poster Presented at the CNS Summit 2016 in Boca Raton, Florida, October 27-30, 2016

Gregory M. Sullivan, Perry Peters, R. Michael Gendreau, Judith F. Gendreau, Ashild Peters, Jean M. Engels, Amy Schaberg, Heather Jividen, Seth Lederman

Tonix PTSD Awareness Day - October 26, 2016
Dr. Seth Lederman – Welcome and Introduction

Tonix PTSD Awareness Day - October 26, 2016
Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD

Tonix PTSD Awareness Day - October 26, 2016
Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations

Tonix PTSD Awareness Day - October 26, 2016
Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD

The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

Poster Presentation at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 15-18, 2016

Sullivan GM, Gendreau JF, Gendreau RM, Schaberg A, Daugherty BL, Jividen H, Peters A, Peters P, Lederman S. The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD. Poster session presented at: 2016 Military Health System Research Symposium (MHSRS); 2016 Aug 15-18; Kissimmee, FL.

TNX-102 SL for the Treatment of Fibromyalgia - Comparison of 30% Pain Respondent Analysis with Omeract Draft Composite Responder Endpoint Analyses

Poster Presentation at the European Union League Against Rheumatism 2016 Annual Meeting in London, England June 9, 2016

Gendreau RM, Arnold L, Clauw D, Gendreau J, Vaughn B, Daugherty B, Lederman S. THU0560 TNX-102 SL for the Treatment of Fibromyalgia: Comparison of 30% Pain Responder Analysis with OMERACT Draft Composite Responder Endpoint Analysis. Ann Rheum Dis. 2016; 75(Suppl 2): 394.

A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD

Poster Presentation at the American Society of Clinical Psychopharmacology 2016 Annual Meeting in Scottsdale AZ June 1, 2016

Sullivan GM, Gendreau JF, Gendreau RM, Schaberg A, Daugherty BL, Jividen H, Peters A, Peters P, Lederman S. A Randomized Placebo-Controlled Multicenter Trial of a Low-Dose Bedtime Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD. Poster session presented at: American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting. 2016 May 30 - Jun 3; Scottsdale, AZ.